Requires disclosure and verification of algorithms used in coronary artery disease risk indicators to calculate a patient-specific risk of presence of coronary artery disease.
Requires disclosure of all inputs and outputs of algorithms used in coronary artery disease risk indicators.
Requires manufacturers to divulge the procedure for segmenting, characterizing, and classifying the acoustic signal.
Mandates the verification of the algorithm calculations and validation using an independent data set.
Key facts
🏛️ This document has been enacted by the U.S. Food and Drug Administration.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the private sector, rather than the government.
📜 This document's name is 21 CFR § 870.1420 ("Coronary artery disease risk indicator using acoustic heart signals").
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that address whether humans can understand (a) the mechanisms underlying an AI system’s operation and/or (b) the meaning of the systems’ output in the context of use.
This tag applies to documents that address the ability of an AI system to perform as required, without failure, under the conditions of expected use and over a given period of time, including the entire lifetime of the system.
This tag applies to documents that govern whether, how, and/or to what extent people who are affected by or otherwise have an interest in an AI system have access to relevant information about the system.
This tag applies to documents that require, encourage, etc. the disclosure of information about AI systems by their users, developers, vendors, or others directly involved with the systems to third parties, including but not limited to the general public.
This tag applies to documents that address disclosure of whether and how an AI system is deployed; for example, requiring users of government services to be notified when AI systems are used to determine how the services are provided.
This tag applies to documents that address the form of disclosure of information about AI systems, such that information is required or encouraged to be disclosed in a prescribed, standardized form intended to make the information easily accessible and understandable.
This tag applies to documents that discuss evaluations that assess whether deployed AI systems meet the expectations specified or claimed prior to deployment.
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
§ 870.1420 Coronary artery disease risk indicator using acoustic heart signals.
(a) Identification.
A coronary artery disease risk indicator using acoustic heart signals is a device that records heart sounds including murmurs and vibrations to calculate a patient-specific risk of presence of coronary artery disease, as an aid in cardiac analysis and diagnosis.
Identifies coronary artery disease risk using acoustic heart signals for cardiac analysis and diagnosis.
Identifies coronary artery disease risk using acoustic heart signals for cardiac analysis and diagnosis.
(b) Classification.
Class II (special controls). The special controls for this device are:
(1) Clinical performance testing must fulfill the following:
(i) Testing must include a discussion of the patient population and any statistical techniques used for analyzing the data; and
(ii) Testing must be representative of the intended use population for the device. Any selection criteria or sample limitations must be fully described and justified.
(2) Acoustic performance testing must evaluate microphone sensitivity, sound acquisition bandwidth, and amplitude accuracy. The acoustic sensor specifications and mechanism used to capture heart sounds must be described.
(3) A scientific justification for the validity of the algorithm(s) must be provided. This justification must fulfill the following:
(i) All inputs and outputs of the algorithm must be fully described;
(ii) The procedure for segmenting, characterizing, and classifying the acoustic signal must be fully described; and
(iii) This justification must include verification of the algorithm calculations and validation using an independent data set.
Requires clinical performance, acoustic testing, and algorithm justification for Class II device special controls compliance.
Requires clinical performance, acoustic testing, and algorithm justification for Class II device special controls compliance.
(4) The patient-contacting components of the device must be demonstrated to be biocompatible.
(5) Software verification, validation, and hazard analysis must be performed.
(6) Human factors/usability testing must demonstrate that the user can correctly use the device, including device placement, based solely on reading the directions for use.
(7) Performance data must demonstrate the electromagnetic compatibility and electrical safety of the device.
(8) Labeling must include the following:
(i) A description of what the device measures and outputs to the user;
(ii) Instructions for proper placement of the device;
(iii) Instructions on care and cleaning of the device;
(iv) Warnings identifying sensor acquisition factors that may impact measurement results and instructions for mitigating these factors; and
(v) The expected performance of the device for all intended use populations and environments.